Skip to main content

Table 1 Characteristics of the cases and controls

From: Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

CharacteristicsCasesControls
Low Risk N (%)High Risk without Progression N (%)High Risk with progression N (%)Metastatic N (%)Healthy N (%)
Number of subjects11 (100)12 (100)10 (100)9 (100)10 (100)
Ethnicity
 Caucasian11 (100)12 (100)10 (100)9 (100)10 (100)
 Median (IQR)Median (IQR)Median (IQR)Median (IQR)Median (IQR)
Age at blood draw (years)61.4 (57.6–64.6)62.9 (60.2–69.3)63.6 (60.6–68.3)59.8 (57–68)38.3 (34–40.6)
PSA at blood draw (ng/mL)5.8 (4.6–6.05)9.32 (6.12–13.6)10.9 (7.65–23.9)NAaNAb
Years between blood draw and event
 PSA progression (or last follow-up)7.59 (7.05–8.44)5.88 (2.99–6.96)0.28 (0.26–0.93)NAaNAb
 local progression (or last follow-up)7.59 (7.05–8.44)6.98 (6.60–7.76)4.04 (1.69–6.77)NAaNAb
 lymphnode progression (or last follow-up)7.59 (7.05–8.44)7.13 (6.88–7.87)3.16 (2.62–4.14)NAaNAb
 bone progression (or last follow-up)7.59 (7.05–8.44)7.14 (6.88–7.87)4.42 (2.09–7.20)NAaNAb
Years in follow-up7.59 (7.05–8.44)7.14 (6.88–7.87)5.11 (4.25–7.94)3.23 (1.77–4.87)NAb
  1. Prostate cancer patient classification is determined according to NCCN guidelines version 1.2018; IQR, interquartile range (25th to 75th percentile)
  2. a The metastatic patients have not received radical prostatectomy and already present with advanced metastatic and progressive prostate cancer at time of blood draw
  3. b The controls are healthy and do not present prostate cancer